%---------------------------------------------------------------------------

\begin{table*}[]
\small
  \centering
   \caption{Treatment efficacy on mood disturbances}
  \label{tab:e3}
\begin{tabular}{lllclclll}
 \hline
 &&&&&&&\\
& 
\pbox{2cm}{Sample\\characteristics} &
\pbox{1cm}{Design\\} &
\pbox{2cm}{Study\\Timeframe} &
\pbox{1.5cm}{Treatment\\protocol} &
 & 
\pbox{2cm}{Primary\\outcome\\measures} & 
\pbox{2cm}{Results\\} \\
&&&&&&&\\
&
Size ($\dagger$)
&
&
\emph{(weeks)}&
Dosage &
Duration &
&
\\
 \hline
 &&&&&&&\\
%------------------------------------------------------------
\pbox{3cm}{Johnson 2003\\ \cite{johnson_ondansetron_2003}}
& \pbox{1cm}{253 (C)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{12\\}
& \pbox{3cm}{ OND:\\ 1 µg/kg bid\\4 µg/kg bid\\ 16 µg/kg bid}
& \pbox{1cm}{11 w\\}
& \pbox{2cm}{Mood (Profile of Mood States}
& \pbox{4cm}{OND 16 µg/kg bid was effective* on reducing some mood disturbances in EOA}\\
%-----------------
&&&&&&&\\
\pbox{3cm}{Sherwood 2021\\ \cite{sherwood_brown_randomized_2021}}
& \pbox{1cm}{70 (K)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{12 \\}
& \pbox{3cm}{OND\\0.5/1/2 or 4 mg\\(3.23 ± 2.64 mg)}
& \pbox{1cm}{12 w\\}
& \pbox{2cm}{HRSD, IDS-SR, YMRS}
& \pbox{4cm}{Reduction in HRSD in ondansetron group vs control*. N.S. for other measures}\\

%-----------------------------
&&&&&&&\\
 \hline
\end{tabular}
\caption*{\emph{\input{other/legends}}}
\end{table*}
%---------------------------------------------------------------------------
